Biomea Fusion: FDA Lifts Hold on Diabetes-Treatment Trials
Biomea Fusion Inc BMEA
News
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, Inc. (NASDAQ: BMEA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Biomea Fusion Down 61% on Clinical Hold for Diabetes Drug
United States